OBJECTIVE: To examine the relationship of obesity, body fat distribution, and fasting plasma insulin concentrations with the plasma levels of both pro-thrombotic and anti-thrombotic factors in premenopausal women. SUBJECTS: 32 obese women with BMI b 28 and 33 age-matched non-obese women with BMI`25. MEASUREMENTS: (i) plasma concentrations of plasminogen activator inhibitor-1 antigen (PAI-1 Ag), plasminogen activator inhibitor-1 activity (PAI-1 activity), ®brinogen, von Willebrand factor antigen (vWF Ag), von Willebrand factor activity (vWF activity), and factor VII activity as pro-thrombotic factors; (ii) plasma concentrations of tissue plasminogen activator antigen (t-PA Ag), protein C, and antithrombin III as anti-thrombotic factors; (iii) fasting plasma insulin and glucose concentrations, and the lipid pattern (triglycerides, total and HDL-cholesterol) as metabolic parameters. The body fat distribution was evaluated by measuring the waist circumference and the waist-to-hip ratio (WHR). RESULTS: Obese subjects had higher plasma concentrations of all pro-thrombotic factors as compared to non-obese controls (PAI-1 Ag, P`0.001; PAI-1 activity, P`0.05; ®brinogen, P`0.001; vWF Ag, P`0.001; vWF activity, P`0.05; factor VII, P`0.05). The plasma concentrations of PAI-1 Ag and vWF Ag were directly correlated with the waist circumference independently of other metabolic and non-metabolic variables (P`0.05). Obese women were also characterized by higher plasma concentrations of anti-thrombotic factors such as t-PA Ag and protein C as compared to non-obese controls (P`0.001 and P`0.001, respectively), although these factors were not independently correlated with the waist circumference or the WHR. CONCLUSION: Plasma concentrations of the pro-thrombotic factors are increased in obese women as compared to non-obese controls, and plasma levels of PAI-1 Ag and vWF Ag correlate with central fat accumulation speci®cally. Plasma concentrations of anti-thrombotic factors (namely protein C and t-PA Ag) are also raised in obese women, but they are not correlated with parameters of body fat distribution. The increase in protein C levels may represent a protective response partly counteracting the increase in pro-thrombotic factors in these individuals.
Introduction
Obesity and central fat accumulation in particular are known to represent risk factors for the development of deep venous thrombosis 1 and coronary heart disease (CHD). 2±5 The increased prevalence of thrombotic events in individuals with excess of body fat has been related to the various metabolic and non-metabolic abnormalities associated with obesity that include insulin-resistance, hyperinsulinaemia, impaired glucose metabolism, hypertriglyceridaemia, low HDL-cholesterol levels, and hypertension. 2±13 Each of these abnormalities may favour the atherosclerotic process and increase the occurrence of thrombotic events through multiple and distinct mechanisms. In particular, these metabolic and non-metabolic abnormalities have been shown to affect the endothelium and the coagulation system, which play an important role in the disease process.
14 Imbalance in the haemostatic system secondary to increased clotting activity, impaired ®brinolytic activity, or a combination of both has the potential to in¯uence the growth and ®nal size of evolving thrombi and predispose to arterial occlusion. 14 It should be noted that the hypercoagulable state may also promote thrombosis at the site of a suddenly ruptured atherosclerotic plaque in the coronary circulation. 14 Recent epidemiological studies have shown that an increase in certain pro-thrombotic factors such as ®brinogen, factor VII, von Willebrand factor (vWF), and plasminogen activator inhibitor-1 (PAI-1) may be predictive of CHD in obese as well as in nonobese subjects. 15±28 Recently, an increase in prothrombotic factors such as ®brinogen, these studies, the increases in plasma concentrations of ®brinogen, factor VII, and PAI-1 were more pronounced in obese individuals with higher waist to hip ratio (WHR) 29,30,33±40 and visceral fat accumulation. 31 However, several issues present in these previous studies make the potential role of the coagulative system in central obesity dif®cult to evaluate. Some studies were conducted on subjects of both sexes and with a wide range of age, 15±20,30 or only in men, 31 or on subjects that were only moderately overweight. 38 In addition, the investigation of the factors involved in the regulation of the coagulation process has often not been complete because only some of the pro-thrombotic factors have been considered, and the in¯uence of factors that mediate the ®brinolytic process andaor inhibit coagulation such as tissue plasminogen activator (t-PA), antithrombin-III, and protein C has not been assessed. The latter factors counteract the thrombotic process under physiological conditions and have been demonstrated to exert a protective effect against the risk of thrombosis. 17, 18, 41 Thus, they may represent a fundamental determinant of the overall risk of atherosclerosis and thrombosis in individuals with excess body fat.
The objective of this study was to examine the relationships of both pro-thrombotic and anti-thrombotic factors with obesity, body fat distribution, insulin levels, and the lipid pattern in non-smoking premenopausal women. The plasma concentrations of ®brinogen, vWF Ag, vWF activity, factor VII, PAI-1 Ag, and PAI-1 activity were determined as pro-thrombotic factors. In addition, the plasma levels of antithrombin-III, protein C, and t-PA Ag were evaluated as anti-thrombotic factors. Body fat distribution was evaluated by measuring the WHR or the waist circumference, which has recently been shown by Pouliot et al. 42 to re¯ect the extent of abdominal visceral fat deposition. Finally, we measured fasting serum insulin, blood glucose, and serum lipids concentrations because they represent important metabolic parameters that are altered in obese individuals and are known to be regulated by the pattern of body fat distribution.
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Materials and methods
Subjects
This study enrolled 63 women, represented by 30 obese (BMI ! 28) and 33 non-obese (BMI 25) subjects. The obese patients were consecutively recruited at the Outpatient Clinic for the Study of Obesity of the Institute of Internal Medicine, Endocrinology, and Metabolic Diseases of the University of Bari School of Medicine. Normal weight women were represented by apparently healthy volunteers consecutively recruited among physicians and students of Medicine. All participants gave their informed consent to be enrolled in the study. Women had no history or physical or ECG signs of coronary heart disease. Biochemical markers of thyroid, liver, and kidney function were in the normal range in all subjects. All subjects had a normal glucose tolerance, as determined by the World Health Organization (WHO) criteria. 43 All subjects were not regular smokers, in the sense that none of them would smoke more than one cigarette per week; two patients in the obese group were ex-smokers, but they had stopped smoking over one year before enrolment in the study. All subjects were asked not to take any drug for at least 15 d before the tests. Women were all menstrually active (9±13 menses per year) and had not taken oral contraceptives during the last six months. During the six months prior to the study, they were also asked to keep their normal isocaloric diet and not to perform any intense athletic activity.
Blood pressure was recorded on at least three separate occasions, using a mercury manometer with an appropriate cuff size (Baumanometer, Baum, New York, NY). Blood samples for hormonal, metabolic, and haemostatic determinations were drawn between 8 am and 9 am after an overnight fast. The oral glucose tolerance test (OGTT) was performed by collecting venous blood samples at fasting and every 30 min for 2 h following an oral load of 75 g glucose, and the resulting samples were used for plasma glucose and serum insulin measurements. To avoid the potential in¯uence of changes of sex hormone levels on haemostatic and metabolic parameters, all blood samples were taken during the follicular phase (on day 5±7 of the menstrual cycle).
Metabolic parameters
Blood glucose concentrations were determined by the glucose-oxidase method (Sclavo, Siena, Italy). Total cholesterol, triglycerides, and HDL-cholesterol were measured with enzymatic assays (Boehringer Mannheim, GMbH Diagnostica Mannheim, Germany). Serum insulin concentrations were measured by RIA using a commercially available kit (Behring, Scoppitto, Italy). Both the intra-assay and inter-assay coef®cients of variation in all of the above methods were less than 7.5%.
Haemostatic parameters
For measurements of haemostatic parameters, subjects were placed at rest in the supine position for 20 min. Then, venous blood (25 ml) was drawn using a no. 19 butter¯y needle without venous stasis and discarding the ®rst 3 ml. Blood samples were drawn in siliconized vacutainer tubes, containing sodium citrate (0.38% ®nal concentration). Plasma samples for factor VII and ®brinogen determinations were always handled at room temperature and never held at 4 C to avoid cold activation, and measurements were carried out on the same day of blood collection. Blood samples for other haemostatic determinations were kept on crushed ice until centrifugation. Samples were centrifuged at 2.500 6 g for 15 min at 4 C within 15 min after blood collection. The resulting plasma was stored in small aliquots in a 770 C freezer until assay.
Plasma factor VII was determined by a one-stage clotting assay using thromboplastin (PT-Fibrinogen HS, Instrumental Laboratory, Milan, Italy), a factor VII-de®cient plasma (Instrumental Laboratory, Milan, Italy), a control plasma (Instrumental Laboratory, Milan, Italy), and a plasma pool from our laboratory.
Fibrinogen concentrations were determined according to the method of Clauss 44 using a commercially available kit (Ortho Diagnostic Systems, Raritan, New Jersey, USA).
vWF activity was evaluated by a modi®cation of the Weiss test. 45 vWF Ag was quanti®ed by an enzyme-linked immunoadsorbent assay (ELISA) (Boehringer Mannheim, Asnieres, France). For vWF Ag measurements, we used plastic tubes coated with speci®c rabbit anti-human vWF antibodies that bind vWF in the test plasma. Anti-rabbit vWF antibodies coupled with peroxidase were then added to bind to the remaining free antigenic determinants of vWF, and bound peroxidase was revealed by its activity on o-phenylendiamine in the presence of hydrogen peroxide. A standard curve for this method was prepared with a universal reference plasma, and the results were reported as a percentage of the standard.
Antithrombin-III was determined by the chromogenic substrate method using a commercially available colorimetric assay (Instrumentation Laboratory, Milan, Italy) and calibrating against Antithrombin-III calibrator (Instrumentation Laboratory, Milan, Italy).
Measurements of plasma protein C concentrations were performed by an automated functional assay based on the prolongation of the APTT (Instrumentation Laboratory, Milan, Italy), using the ACL 2000 device (Instrumentation Laboratory, Milan, Italy).
PAI-1 Ag concentrations were determined by an ELISA assay (Boehringer Mannheim, Asnieres, France) and PAI-1 activity was measured by a photometric determination method (Kabivitrum, Molndal, Sweden), as previously described. 37, 38 Plasma t-PA Ag concentrations were quantitated by an ELISA method (Boehringer Mannheim, Asnieres, France), similar to the determination of vWF Ag. Results were reported as a percentage of the standard.
Both intra-assay and inter-assay coef®cients of variation in all of the above determinations were less than 7.5%.
Waist and WHR measurements
The waist circumference was measured as the minimum measurement between the xyphoid process and umbilicus. The hip circumference was measured at the most protruding points of the greater trocanthers.
Statistical analyses
Results are presented as means AE s.e.m. A logarithmic transformation (log 10 ) of the values was performed for not normally distributed variables (for example PAI-1 Ag and triglycerides). The unpaired Student's t-test was used to compare mean values among obese and non-obese women. Pearson correlation coef®cients were used to quantify the univariate associations among variables. A stepwise multiple regression analysis was carried out to test the joint effect of different variables on haemostatic parameters in all subjects.
Results
The clinical characteristics and metabolic parameters of obese subjects compared to non-obese controls are illustrated in Table 1a .
Plasma concentrations of haemostatic factors in obese and non-obese subjects are shown in Table  1b . Correlation coef®cients between haemostatic parameters and BMI, WHR, waist circumference, and blood pressure levels in obese and normal weight subjects are shown in Table 2 and Table 3 , respectively.
The results in Tables 4 and 5 illustrate additional correlations found between haemostatic factors and other metabolic and non-metabolic parameters.
A stepwise multiple regression analysis was carried out to test the joint effect of different variables on haemostatic parameters in all subjects. These analyses are not shown for those factors that were not associated independently with any anthropometric or metabolic parameter (®brinogen, factor VII, vWF activity, protein C and antithrombin-III).
When PAI-1 Ag was considered as the dependent variable, insulin was the ®rst variable to enter into the model, followed by age and waist circumference, and PAI-1 Ag maintained an independent association only with insulin (t-value: 2.150; P`0.05) and waist circumference (t-value 2.452; P`0.05) (®tted model: R 2 adjusted 0.385; F ratio 3.92; P-value`0.01).
When PAI-1 activity was tested as the dependent variable, triglycerides was the ®rst variable to enter into the model, and PAI-1 activity maintained an independent signi®cant correlation only with triglycerides (t-value 2.125; P`0.05) and BMI (t-value 3.60; P`0.01) (®tted model: R 2 adjusted 0.63; F ratio 6.59; P-value`0.001).
An independent correlation between vWF Ag and the waist circumference (t-value 2.38; P`0.05; ®tted model: R 2 adjusted 0.635; F ratio 5.61; P value`0.01) and between t-PA Ag and BMI (t-value 4.53; P`0.001; ®tted model: R 2 adjusted 0.644; F ratio 5.69; P-value`0.01) were also found. Results are expressed as means AE s.e.m. Differences between the groups: **P`0.01; ***P`0.001. Values were log-10 transformed. PAI-1, plasminogen activator inhibitor-1; t-PA, tissue plasminogen activator. WC, waist circumference; WHR: waist-to-hip ratio; SBP, systolic blood pressure; DBP: diastolic blood pressure.
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G De Pergola et al PAI-1 Ag (r: 0.43; P`0.05), factor VII (r: 0.42; P`0.05), t-PA Ag (r: 0.49; P`0.01), and protein C (r: 0.396; P`0.05) showed a positive correlation with the age of the subjects only in the obese group.
Discussion
The objective of this study was to investigate whether obesity and central fat accumulation are associated with altered plasma concentrations of haemostatic factors in premenopausal women. Obese women showed increased plasma concentrations of all procoagulant factors investigated (PAI-1 Ag, PAI-1 activity, ®brinogen, factor VII, vWF Ag, and vWF activity). These results con®rm that an excess body fat is associated with increased plasma concentrations on PAI-1, ®brinogen, factor VII, and vWF.
PAI-1 Ag, vWF Ag, and factor VII were signi®-cantly correlated with the waist circumference in obese women. Interestingly, the association of both PAI-1 Ag and vWF Ag with the waist circumference was independent of BMI and other parameters investigated. Taken together, these results indicate that accumulation of central fat is speci®cally associated with higher plasma concentrations of pro-thrombotic factors in obese premenopausal women. Noteworthy, PAI-1 Ag was correlated with the waist circumference even in normal weight women. On the other hand, the WHR showed a positive correlation only with PAI-1 Ag, and only in obese women.
Obese subjects had higher plasma concentrations of ®brinogen compared to controls, but ®brinogen was Values were log-10 transformed. PAI-1 plasminogen activator inhibitor-1; t-PA, tissue plasminogen activator, WC, waist circumference; WHR: waist-to-hip ratio; SBP, systolic blood pressure; DBP: diastolic blood pressure. Values were log-10 transformed. PAI-1, plasminogen activator inhibitor-1; t-PA, tissue plasminogen activator; TG, triglycerides; Chol, cholesterol; HDL-chol, HDL-cholesterol.
Thrombotic risk factors and fat distribution G De Pergola et al positively correlated with BMI only in normal weight women. These results suggest that, although ®brino-gen is signi®cantly associated with BMI in normal weight women, other factors may be more important than BMI per se in increasing ®brinogen levels in obese women. In subjects with central obesity the increase in PAI-1 and vWF Ag may be more important than the increase in ®brinogen for the risk of CHD. This concept is supported by our ®nding of an independent relationship between plasma levels of pro-thrombotic factors, in particular PAI-1, and central fat accumulation. Our data are in line with a recent study by Palareti et al., who did not ®nd signi®cant associations of ®brinogen plasma levels with either the WHR or insulin levels 40 and with epidemiological studies such as the Augsburg MONICA survey, 16 the ARIC study, 17 and the Northern Sweden MONICA study, 30 in which it was shown that central obesity is predictive of ®brinogen levels in men, whereas only obesity per se is predictive of ®brinogen levels in women. These studies underline the importance of studying each gender separately while conducting studies on haemostatic factors. On the other hand, this study is apparently in contrast with previous studies by Landin et al. 35 showing a signi®cant positive correlation of plasma ®brinogen concentrations with fasting insulinaemia and the extent of insulin-resistance. 46 However, the insulin-®brinogen relationship may depend upon accompanying factors such as acute-phase proteins rather than insulin levels per se, as suggested by Juhan-Vague et al. 47 In addition, ®brinogen levels have been shown to be unaffected by strategies that reduce insulin levels and are effective on other pro-thrombotic factors (namely PAI-1 and factor VII) such as weight loss in obese patients. 38, 40 Finally, the EARS study has recently shown that ®brinogen is a transmissible risk factor of CHD, 19 and variation in the gene locus coding for ®brinogen may contribute more than environmental factors to the plasma ®brinogen levels. 48 PAI-1 Ag was also correlated with metabolic parameters such as fasting serum insulin concentrations and blood glucose, but it was independently correlated only with insulin. Plasma insulin has been proposed to be a major physiological regulator of PAI-1 levels in plasma and therefore of ®brinolytic activity. 47 A stimulatory effect of insulin on the synthesis and release of PAI-1 has been demonstrated in vitro using HepG2 cells in culture. 49, 50 Hyperinsulinaemia may thus be responsible for the PAI-1 elevation seen in obese individuals, 14 and the reduction of insulin levels by weight loss 38 or other strategies (exercise, metformin, etc.) may explain the concomitant decrease in plasma PAI-1 activity. Finally, a strong relationship between plasma insulin and PAI-1 levels was found in the ECAT study on 1500 patients with angina pectoris. 51 Altogether, these ®ndings support the concept that the increase in plasma PAI-1 Ag levels may be considered as an additional component of the insulin resistance syndrome.
14 Since in this study PAI-1 Ag was signi®cantly associated with insulin in obese but not in normal weight subjects, it could be hypothesized that hyperinsulinaemia but not insulin per se may be important for the increase in PAI-1 Ag levels. PAI-1 activity was also positively correlated with blood glucose and triglycerides levels and negatively correlated with HDL-cholesterol in obese patients. However, PAI-1 actively maintained an independent relationship only with triglycerides after adjustment for anthropometric and metabolic parameters. It is possible that triglycerides might directly in¯uence PAI-1 production. This hypothesis is supported by in vitro studies showing that triglyceride-rich puri®ed VLDL lipoproteins directly increase the synthesis of PAI-1 by endothelial and liver cells. 52 Thus, plasma concentrations of triglycerides may represent an important determinant of PAI-1 activity in obese women. Some indication that the regulation of PAI-1 activity by triglycerides may be con®ned to individuals with a speci®c genotype has been provided by recent studies. Dawson et al. 53 genotyped young postinfarction patients and population-based controls for two polymorphisms at the PAI-1 locus including a HindIII restriction fragment length polymorphism and a (CA)n dinucleotide repeat polymorphism that occurs in intron 3 of the gene. An association of plasma PAI-1 activity was found with the HindIII genotype within both the case and control groups, with the 1a1 genotype exhibiting higher PAI-1 levels than the 2a2 genotype. Subjects with the HindIII genotype 1a1 had two-to three-fold higher plasma PAI-1 activity in the presence of raised VLDL triglycerides concentrations as compared to individuals with the genotype 2a2. The authors suggested that the HindIII polymorphism is in linkage disequilibrium with a base change at a site of functional importance in the regulation of PAI-1 by VLDL. A candidate site could be a sequence in the PAI-1 gene involved in the binding of a transcriptional factor, the level of which is in¯uenced by VLDL concentrations andaor composition. In addition, a common single base pair 4a5-guanosine (4Ga5G) polymorphism (GACACGTG 4 or 5 AGT) was recently detected in the promoter region of the PAI-1 gene and shown to be associated with altered plasma PAI-1 activity among long-term survivors of myocardial infarction. Individuals possessing the 4G allele were found to have higher plasma PAI-1 activity than individuals with at least one 5G allele. 54 A clinical consequence of the genotype-speci®c regulation of plasma PAI-1 activity by triglyceride levels would be that certain hypertriglyceridaemic individuals, depending on their genotype, may be more prone to suffer thrombotic complications than others. It is possible that speci®c genetic abnormalities may also play a role in the higher levels of PAI-1 Ag and triglycerides of the obese women investigated in this study.
Plasma concentrations of factor VII were associated with systolic blood pressure levels in obese women. In addition, we found a positive correlation between factor VII and insulin levels which is in line with the results of previous studies. 40, 46 It should be noted, however, that the correlation of factor VII with insulinaemia found in this study was not maintained after multiple regression analysis, and this is in line with the study by Juhan-Vague et al. 47 who suggested that the previously observed link between insulin and factor VII may be due to nonspeci®c endothelial cell damage.
Plasma levels of both vWF Ag and vWF activity were not correlated with insulin, blood glucose, lipids, or blood pressure levels. These ®ndings support the concept that vWF plasma concentrations may be unrelated to the metabolic factors involved in the insulin resistance syndrome. 55 The determination of plasma concentrations of antithrombotic factors showed that obese women were characterized by elevated plasma concentrations of protein C and t-PA Ag as compared to non-obese women. These results are in line with previous studies showing positive correlations between obesity and protein C 21 and obesity and t-PA. 38 On the other hand, con¯icting results have been reported on the effects of BMI on antithrombin III activity. 56 In this study, we could not ®nd signi®cant differences in antithrombin III levels between obese and non-obese women and no correlation between antithrombin III and BMI was observed in either obese or normal weight women. Since elevated t-PA antigen appears to be a regular accompaniment of elevated PAI-1 antigen due to the presence of increased t-PA-PAI-1 complexes, 57 then the increase in t-PA levels in obese subjects may re¯ect a higher risk of thrombosis. This hypothesis is supported by recent studies showing that raised t-PA Ag levels are associated with peripheral atherosclerosis 58 and are predictive of long-term mortality in patients with CAD. 59, 60 On the other hand, the increase in protein C levels in obese subjects may indicate a protective response that opposes the risk of thrombosis resulting from higher concentrations of pro-thrombotic factors and occurs in advance of possible future vascular occlusion.
Plasma concentrations of t-PA Ag, protein C, and antithrombin-III did not show an independent correlation with the waist circumference or the WHR, suggesting that the increase in anti-thrombotic factors in obese women is independent of the pattern of fat distribution. Protein-C levels were positively correlated with both systolic and diastolic blood pressure levels, but these associations were not maintained after multiple stepwise regression. Moreover, t-PA Ag, protein C, and antithrombin III levels did not show an independent signi®cant relationship with any of the metabolic parameters investigated. However, the lack of correlation does not exclude the possibility that insulin, blood glucose, or the lipid pattern may play an important role in regulating the production of anti-thrombotic and ®brinolytic factors in obese women.
Conclusions
This study shows that: (i) obesity is characterized by increased plasma concentrations of pro-thrombotic factors (PAI-1 Ag, PAI-1 activity, vWF Ag, vWF activity, factor VII, and ®brinogen); (ii) the increase in PAI-1 Ag and vWF Ag plasma concentrations is independently associated with central fat accumulation as assessed by measuring the waist circumference; (iii) in obese women, plasma levels of prothrombotic factors such as PAI-1 Ag, vWF Ag, and factor VII are associated with the waist circumference more strongly than with the WHR; and (iv) some antithrombotic and ®brinolytic factors such as protein C and t-PA are also elevated in obese subjects. These ®ndings may provide an additional explanation for the increased risk of thrombosis in individuals with central obesity. On the other hand, the rise in plasma levels of protein C may represent an important compensatory response with the signi®cance of opposing the increased levels of pro-thrombotic factors.
